In accordance with Sec. 704 of the FY 2015 National Defense Authorization Act, TRICARE will consider as evidence that a compound ingredient is safe and effective:
Clinical trial published in refereed medical literature
Formal technology assessments
The positions of national medical policy organizations, national professional organizations or national expert opinion organizations
Other validated evidence as the Secretary of Defense considers appropriate